Azole-mediated CYP3A inhibition and persistent gastrointestinal GVHD increase tacrolimus oral bioavailability after allo-HSCT.

Matsukane R, Takahira M, Mori Y, Yamauchi T, Yasukochi S, Nakamura S, Ishida S, Suetsugu K, Kawashiri T, Kato K, Akashi K, Kikushige Y, Uchida M

Open source

DOI: 10.1093/jjco/hyag193
Published: 2026 Nov 10
Container: Japanese journal of clinical oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/jjco/hyag193,
  title = {Azole-mediated CYP3A inhibition and persistent gastrointestinal GVHD increase tacrolimus oral bioavailability after allo-HSCT.},
  author = {Matsukane R and Takahira M and Mori Y and Yamauchi T and Yasukochi S and Nakamura S and Ishida S and Suetsugu K and Kawashiri T and Kato K and Akashi K and Kikushige Y and Uchida M},
  year = {2026},
  journal = {Japanese journal of clinical oncology},
  doi = {10.1093/jjco/hyag193},
  url = {https://doi.org/10.1093/jjco/hyag193}
}

RIS

TY  - JOUR
TI  - Azole-mediated CYP3A inhibition and persistent gastrointestinal GVHD increase tacrolimus oral bioavailability after allo-HSCT.
AU  - Matsukane R
AU  - Takahira M
AU  - Mori Y
AU  - Yamauchi T
AU  - Yasukochi S
AU  - Nakamura S
AU  - Ishida S
AU  - Suetsugu K
AU  - Kawashiri T
AU  - Kato K
AU  - Akashi K
AU  - Kikushige Y
AU  - Uchida M
PY  - 2026
JO  - Japanese journal of clinical oncology
DO  - 10.1093/jjco/hyag193
UR  - https://doi.org/10.1093/jjco/hyag193
ER  -

APA

R, M., M, T., Y, M., T, Y., S, Y., S, N., S, I., K, S., T, K., K, K., K, A., Y, K., & M, U. (2026). Azole-mediated CYP3A inhibition and persistent gastrointestinal GVHD increase tacrolimus oral bioavailability after allo-HSCT.. Japanese journal of clinical oncology. https://doi.org/10.1093/jjco/hyag193

Source records

pubmed · retrieved 2026-11-11T00:39:53.143Z